Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Silvana Mourón(Spanish National Cancer Research Centre), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), Marcos Malumbres(Institució Catalana de Recerca i Estudis Avançats), Juan Miguel Cejalvo(Universitat de València), Sergio Sabroso‐Lasa(Spanish National Cancer Research Centre), Aňa Lluch(Hospital Clínico Universitario de Valencia), José Á. García-Sáenz(Hospital Clínico San Carlos), Pilar Ximénez‐Embún(Spanish National Cancer Research Centre), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Núria Malats(Spanish National Cancer Research Centre), Lucía González‐Cortijo(Hospital Universitario Quirónsalud Madrid), A. Moreno(Hospital Universitario de Fuenlabrada), Javier Muñoz(Ikerbasque), Luís Manso(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Rámón Colomer(Hospital Universitario de La Princesa), Mario Martínez-López(Hospital Universitario 12 De Octubre), Javier Cortés(Villa Maria Hospital), Isabel Calvo(MD Anderson Cancer Center Madrid), Gonzalo Goméz-López(Spanish National Cancer Research Centre), Diego Megı́as(Spanish National Cancer Research Centre), María J. Bueno(Spanish National Cancer Research Centre), Noelia Martínez-Jáñez(Instituto Cajal), Juan V. Apala(Spanish National Cancer Research Centre), Eduardo Caleiras(Spanish National Cancer Research Centre), Raquel Murillo(Hospital Universitario Quirónsalud Madrid), Coral Fustero‐Torre(Spanish National Cancer Research Centre)
Nature Communications
December 7, 2022
10.1038/s41467-022-35065-z
Cited by 14

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k